We are live on ! Find out more
NC

Nexthera Capital Portfolio holdings

AUM $120M
1-Year Est. Return 10.01%
This Fund
S&P 500
This Quarter Est. Return
+19.11%
1 Year Est. Return
+10.01%
3 Year Est. Return
+160.68%
5 Year Est. Return
–
10 Year Est. Return
–
AUM
$196M
AUM Growth
+$25.4M
Cap. Flow
+$6.53M
Cap. Flow %
3.33%
Top 10 Hldgs %
68.13%
Holding
55
New
16
Increased
5
Reduced
7
Closed
19

Top Buys

Rank Stock Value
1
PFE icon
Pfizer
PFE
+$15.5M
2
GSK icon
GSK
GSK
+$12.8M
3
VNDA icon
Vanda Pharmaceuticals
VNDA
+$7.3M
4
NDRM
NeuroDerm Ltd. Ordinary Shares
NDRM
+$7.13M
5
GBT
Global Blood Therapeutics, Inc.
GBT
+$3.64M

Top Sells

Rank Stock Value
1
NVS icon
Novartis
NVS
+$14.4M
2
AZN icon
AstraZeneca
AZN
+$8.73M
3
HZNP
Horizon Therapeutics Public Limited Company Ordinary Shares
HZNP
+$8.09M
4
ALNY icon
Alnylam Pharmaceuticals
ALNY
+$6.18M
5
NBIX icon
Neurocrine Biosciences
NBIX
+$4.64M

Sector Composition

Rank Sector Weight
1 Healthcare 70.2%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
ADMS
51
DELISTED
Adamas Pharmaceuticals
ADMS
– –
-151,670
Closed -$2.56M
XLRN
52
DELISTED
Acceleron Pharma
XLRN
– –
-178,000
Closed -$4.54M
HZNP
53
DELISTED
Horizon Therapeutics Public Limited Company Ordinary Shares
HZNP
– –
-500,000
Closed -$8.09M
ZGNX
54
DELISTED
Zogenix, Inc.
ZGNX
– –
-150,000
Closed -$1.82M
IMDZ
55
DELISTED
Immune Design Corp.
IMDZ
– –
-198,600
Closed -$1.09M
1 2
3

Similar funds

KAM
Kavi Asset Management New York $121M AUM 7.54% 1-Year Est. Return
VCP
Vernier Capital Partners New York $132M AUM 20.75% 1-Year Est. Return
PFC
Personal Financial Consultants Lafayette, California $133M AUM 5.06% 1-Year Est. Return
FCA
Florence Capital Advisors New York $105M AUM
TA
TMD & Associates Scottsdale, Arizona $146M AUM 1.29% 1-Year Est. Return
EBIM
Eagle Boston Investment Management Boston, Massachusetts $87.3M AUM 4.18% 1-Year Est. Return
BCM
BBT Capital Management Fort Worth, Texas $85.5M AUM 11.09% 1-Year Est. Return
ACP
ArcLight Capital Partners Boston, Massachusetts $83.2M AUM 32.11% 1-Year Est. Return

Nexthera Capital's Q1 2017 Portfolio in Review

As of Q1 2017, Nexthera Capital held 55 positions worth $196M, up 15% from $171M the previous quarter. Its ten largest holdings account for 68% of the portfolio.

Nexthera Capital deployed $6.53M of net new capital in Q1 2017, opening 16 new positions and adding to 5 existing holdings. Its largest new stake was GSK: 253,200 shares worth $13.3M.

By sector, the portfolio is most concentrated in Healthcare at 70% of assets, down from 83% a quarter earlier.

On the sell side, the largest reduction was Shire pic, an estimated $4.54M trimmed.

  • Nexthera Capital's largest Q1 2017 buy was GSK: 253,200 shares worth $13.3M.
  • Nexthera Capital added most to Pfizer in Q1 2017, an estimated $15.5M increase.
  • Nexthera Capital's biggest Q1 2017 reduction was Shire pic, cutting an estimated $4.54M.
  • Nexthera Capital fully exited Novartis in Q1 2017, selling an estimated $14.4M.
  • Nexthera Capital's ten largest holdings make up 68% of its $196M portfolio in Q1 2017.
  • Nexthera Capital opened 16 new positions and closed 19 in Q1 2017.
  • Nexthera Capital's portfolio value rose 15% quarter-over-quarter to $196M.

Based on Nexthera Capital's 13F filing for Q1 2017, filed 15 May 2017.